Aliskiren

Revision as of 20:25, 4 February 2018 by Jonwarren (talk | contribs) (Creation of page)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Antihypertensive
  • Dosage Forms: 150mg, 300mg
  • Routes of Administration: Oral
  • Common Trade Names:

Adult Dosing

Hypertension

  • 150-300 mg PO qd

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

Renal Dosing

  • Adult:
    • CrCl > 30: No adjustment
    • CrCl < 30: Not Definied
    • HD/PD: No Supplement
  • Pediatric: Safety/efficacy not established in pediatric patients

Hepatic Dosing

  • Adult: No adjustment
  • Pediatric: Safety/efficacy not established in pediatric patients

Contraindications

  • Allergy to class/drug
  • Pregnancy

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 24h
  • Metabolism: Liver partially; 3A4 substrate
  • Excretion: Urine (25% unchanged)

Mechanism of Action

  • Decreases plasma renin activity via direct inhibition
  • Interferes with conversion of angiotensinogen to angiotensin I

Comments

See Also

References